CatSci Ltd, an award-winning innovation partner for medicines development, are pleased to share that we have become members of the Cannabis Industry Council (CIC).
As part of our continuous evolution, we are proud to be joining the Cannabis Industry Council. The Cannabis Industry Council is a leading membership organisation that represents the entire UK cannabis industry. They bring together organisations, business and groups working in different ways to promote the cause of medical cannabis, hemp, and CBD. Our partnership with the CIC aligns with CatSci’s values as their mission is to enhance patient access, thus improving lives by enabling access to medical cannabis products.
Our highly-qualified technical team, state-of-the-art analytical equipment and collaboration with Shimadzu, the leading experts in cannabinoid analysis, mean that we can deliver the highest quality analytical testing on cannabinoids. We aim to build a comprehensive cannabinoids capability that includes potency, related substances measurement, impurity identification, terpenes, pesticides and heavy metals. We are currently working to GMP principles with a full quality management system and aim to be GMP certified in 2023. CatSci is seeking to build relationships and collaborations with CBD medicinal products producers to accelerate GMP certification, ensuring quality of products for patients.
Duncan Thompson, our Head of Dagenham Site, said: “We are thrilled to join the Cannabis Industry Council. The CIC’s mission is to improve access to cannabis to enhance people’s health, the environment, and the economy. We are proud to be joining them on this mission to get medicinal cannabis products into the hands of patients in need. CatSci possess the skills, equipment, workflows, and expertise to provide GMP testing and analysis for CBD and CBDMP products. As such, we anticipate this capability will be fully operational in 2023, which will be another major milestone for CatSci.”